These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30131003)

  • 1. Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma in children: Report from the AIEOP Soft Tissue Sarcoma Committee.
    Compostella A; Affinita MC; Casanova M; Milano GM; Scagnellato A; Dall'Igna P; Chiaravalli S; Pierobon M; Manzitti C; Zanetti I; Schiavetti A; Sorbara S; Mura RM; Ruggiero A; Ferrari A; Bisogno G
    Tumori; 2019 Apr; 105(2):138-143. PubMed ID: 30131003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of children with stage IV soft tissue sarcoma to topotecan and carboplatin: a phase II window trial of the cooperative soft tissue sarcoma group.
    Bochennek K; Dantonello T; Koscielniak E; Claviez A; Dirksen U; Sauerbrey A; Beilken A; Klingebiel T
    Klin Padiatr; 2013 Nov; 225(6):309-14. PubMed ID: 23946091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
    Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
    J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
    Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
    Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
    Donfrancesco A; Jenkner A; Castellano A; Ilari I; Milano GM; De Sio L; Cozza R; Fidani P; Deb G; De Laurentis C; Inserra A; Dominici C
    Acta Paediatr Suppl; 2004 May; 93(445):6-11. PubMed ID: 15176712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
    Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
    Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR).
    Heinz AT; Ebinger M; Schönstein A; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter MW; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Rößler J; Ljungman G; Klingebiel T; Koscielniak E; Sparber-Sauer M;
    Pediatr Blood Cancer; 2023 Jul; 70(7):e30363. PubMed ID: 37066598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
    Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
    J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Cooper BW; Veal GJ; Radivoyevitch T; Tilby MJ; Meyerson HJ; Lazarus HM; Koc ON; Creger RJ; Pearson G; Nowell GM; Gosky D; Ingalls ST; Hoppel CL; Gerson SL
    Clin Cancer Res; 2004 Oct; 10(20):6830-9. PubMed ID: 15501959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
    J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
    De Ioris MA; Castellano A; Ilari I; Garganese MC; Natali G; Inserra A; De Vito R; Ravà L; De Pasquale MD; Locatelli F; Donfrancesco A; Jenkner A
    Eur J Cancer; 2011 Mar; 47(4):572-8. PubMed ID: 21112775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study.
    Pappo AS; Lyden E; Breneman J; Wiener E; Teot L; Meza J; Crist W; Vietti T
    J Clin Oncol; 2001 Jan; 19(1):213-9. PubMed ID: 11134215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
    Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
    Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
    Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
    J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma.
    Meazza C; Casanova M; Zaffignani E; Luksch R; Podda M; Favini F; Catania S; Biassoni V; Morosi C; Ferrari A
    Med Oncol; 2009; 26(1):67-72. PubMed ID: 18679836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
    J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacing actinomycin-D with Carboplatin for newly diagnosed rhabdomyosarcoma.
    Sezgin G; Acipayam C; Bayram I; Ozkan A; Kupeli S; Tanyeli A
    Asian Pac J Cancer Prev; 2015; 16(8):3351-4. PubMed ID: 25921143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
    Devadas SK; Banavali S
    Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
    Kaufmann SH; Karp JE; Letendre L; Kottke TJ; Safgren S; Greer J; Gojo I; Atherton P; Svingen PA; Loegering DA; Litzow MR; Sloan JA; Reid JM; Ames MM; Adjei AA; Erlichman C
    Clin Cancer Res; 2005 Sep; 11(18):6641-9. PubMed ID: 16166443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
    Koensgen D; Stengel D; Belau A; Klare P; Oskay-Oezcelik G; Steck T; Camara O; Mustea A; Sommer H; Coumbos A; Bogenrieder T; Lichtenegger W; Sehouli J;
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):393-400. PubMed ID: 17922272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.